Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson's disease

Pharmacological Research

Volumn 60, Issue 1, 2009, Pages 41-45

  Mutez, Eugénie ^a   Duhamel, Alain ^b   Defebvre, Luc ^a   Bordet, Régis ^a   Destée, Alain ^a   Kreisler, Alexandre ^a  

^a UNIV LILLE   (France)

^b UNIV LILLE   (France)

Author keywords

Disease modifier effect; Lipid lowering drugs; Parkinson disease; Peroxisome Proliferator Activated Receptor alpha

Indexed keywords

ANTILIPEMIC AGENT; APOMORPHINE; ATORVASTATIN; BROMOCRIPTINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVODOPA; LISURIDE; PERGOLIDE; PIRIBEDIL; PRAVASTATIN; ROPINIROLE; ROSUVASTATIN; SIMVASTATIN;

ANALYSIS OF VARIANCE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE COURSE; DISEASE SEVERITY; DYSLIPIDEMIA; FISHER EXACT TEST; HUMAN; MAJOR CLINICAL STUDY; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STUDENT T TEST; UNIFIED PARKINSON DISEASE RATING SCALE; UNIVARIATE ANALYSIS;

CLOFIBRIC ACID; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 67349156640     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.03.010     Document Type: Article

References (31)

1. Grunblatt E., Mandel S., and Youdim M.B. Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP. Ann N Y Acad Sci 899 (2000) 262-273
2. Fruchart J.C., Duriez P., and Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 10 (1999) 245-257
3. Martin G., Duez H., Blanquart C., Berezowski V., Poulain P., Fruchart J.C., et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 107 (2001) 1423-1432
4. Gelb D.J., Oliver E., and Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 56 (1999) 33-39
5. Fahn S., Elton R.L., and and Members of the UPDRS Development Committee. In: Fahn S., Marsden C.D., Calne D.B., and Goldstein M. (Eds). Recent developments in Parkinson's disease vol. 2 (1987), Macmillan Health Care Information 153-164
6. Lozano A.M., Lang A.E., Galvez-Jimenez N., Miyasaki J., Duff J., Hutchinson W.D., et al. Effect of GPi pallidotomy on motor function in Parkinson's disease. Lancet 346 (1995) 1383-1387
7. Tir M., Devos D., Blond S., Touzet G., Reyns N., Duhamel A., et al. Exhaustive, one-year follow-up of subthalamic nucleus deep brain stimulation in a large, single-center cohort of parkinsonian patients. Neurosurgery 61 (2007) 297-305
8. Rodriguez M.C., Obeso J.A., and Olanow C.W. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 44 Suppl. (1998) 175-188
9. Winikates J., and Jankovic J. Clinical correlates of vascular parkinsonism. Arch Neurol 56 (1999) 98-102
10. Rektor I., Rektorová I., and Kubová D. Vascular parkinsonism-an update. J Neurol Sci 248 (2006) 185-191
11. Ritz B., Ascherio A., Checkoway H., Marder K.S., Nelson L.M., Rocca W.A., et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 64 (2007) 990-997
12. Wolozin B., Wang S.W., Li N.C., Lee A., Lee T.A., and Kazis L.E. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med 19 (2007) 5-20
13. Wahner A.D., Bronstein J.M., Bordelon Y.M., and Ritz B. Statin use and the risk of Parkinson disease. Neurology 70 (2008) 1418-1422
14. de Lau L.M., Koudstaal P.J., Hofman A., and Breteler M.M. Serum cholesterol levels and the risk of Parkinson's disease. Am J Epidemiol 164 (2006) 998-1002
15. Simon C.K., Chen H., Schwarzschild M., and Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 69 (2007) 1688-1695
16. Huang X., Abbott R.D., Petrovitch H., Mailman R.B., and Ross G.W. Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia aging study. Mov Disord 23 (2008) 1013-1018
17. Lieberman A., Lyons K., Levine J., and Myerburg R. Statins, cholesterol, Co-enzyme Q10, and Parkinson's disease. Parkinsonism Relat Disord 11 (2005) 81-84
18. Grosset D., Antonini A., Canesi M., Pezzoli G., Lees A., Shaw K., et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord (2009) 10.1002/mds.22112
19. Evans A.H., Lawrence A.D., Potts J., MacGregor L., Katzenschlager R., Shaw K., et al. Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J Neurol Neurosurg Psychiatry 77 (2006) 317-321
20. Hill M.R., Clarke S., Rodgers K., Thornhill B., Peters J.M., Gonzalez F.J., et al. Effect of peroxisome proliferator-activated receptor alpha activators on tumor necrosis factor expression in mice during endotoxemia. Infect Immun 67 (1999) 3488-3493
21. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 274 (1999) 32048-32054
22. Yoo H.Y., Chang M.S., and Rho H.M. Induction of the rat Cu/Zn superoxide dismutase gene through the peroxisome proliferator-responsive element by arachidonic acid. Gene 234 (1999) 87-91
23. Kreisler A., Gelé P., Wiart J.F., Lhermitte M., Destée A., and Bordet R. Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not. Brain Res 1135 (2007) 77-84
24. Deplanque D., Gelé P., Pétrault O., Six I., Furman C., Bouly M., et al. Peroxisome Proliferator-Activated Receptor-α activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 23 (2003) 6264-6271
25. Obata T., and Yamanaka Y. Protective effect of fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on MPP(+)-induced hydroxyl radical in the rat striatum. Brain Res 860 (2000) 166-169
26. Selley M.L. Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res 1037 (2005) 1-6
27. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., Sanchez-Pascuala R., Hernandez G., Diaz C., et al. Effects of the 3-hydroxy-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101 (1998) 2711-2719
28. Laufs U., and Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273 (1998) 24266-24271
29. Laufs U. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol 58 (2003) 719-731
30. Knott C., Stern G., and Wilkin G.P. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 16 (2000) 724-739
31. Pahan K., Sheikh F.G., Namboodiri A.M., and Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia and macrophages. J Clin Invest 100 (1997) 2671-2679